Wegovy HD vs Zepbound: Which 20% Weight Loss Medication Is Right for You?

Wegovy HD vs Zepbound: Which 20% Weight Loss Medication Is Right for You?

Until April 2026, choosing between Wegovy and Zepbound was relatively straightforward. Wegovy (semaglutide 2.4mg) delivered roughly 15% body weight loss. Zepbound (tirzepatide) delivered roughly 20%. If maximizing weight loss was the priority and both were accessible, the math pointed toward Zepbound.

That calculus changed on March 19, 2026. The FDA approved Wegovy HD — semaglutide at a higher 7.2mg dose — via a National Priority Voucher, completing the review in just 54 days. The STEP UP trial showed 20.7% mean weight loss at 72 weeks. Suddenly, both medications are in the same ballpark.

So the new question isn't "which one works better." It's "which one works better for you." If you're asking "wegovy hd vs zepbound which is better" or "should I switch to Wegovy HD from Zepbound," the answer hinges on your current medication history, GI tolerance, and whether LillyDirect pricing is accessible to you. This guide breaks down the clinical data, side effects, dosing, pricing, and real-world scenarios to help you and your prescriber make that decision.

Quick Comparison Table

Feature	Wegovy HD	Zepbound
Active ingredient	Semaglutide 7.2mg	Tirzepatide
Mechanism	GLP-1 receptor agonist	Dual GLP-1/GIP receptor agonist
Mean weight loss	20.7% (STEP UP, 72 wks)	20.9% (SURMOUNT-1, 15mg, 72 wks)
FDA approval date	March 19, 2026 (weight management)	November 2023 (weight management)
Administration	Weekly subcutaneous injection	Weekly subcutaneous injection
Dose levels	0.25mg → 0.5mg → 1mg → 2.4mg → 3.6mg → 7.2mg	2.5mg → 5mg → 7.5mg → 10mg → 12.5mg → 15mg
Max dose	7.2mg	15mg
List price	~$1,350/mo	$1,060/mo
Self-pay / manufacturer program	NovoCare savings (varies)	LillyDirect $299/mo
Medicare coverage	Yes — Bridge program $50/mo	Yes — Bridge program $50/mo
Key clinical trial	STEP UP	SURMOUNT-1, SURMOUNT-5
Manufacturer	Novo Nordisk	Eli Lilly
Cardiovascular indication	Yes (Wegovy label)	No
Notable unique side effect	Dysesthesia (18.9%)	—

What does the evidence show for Wegovy HD vs Zepbound weight loss?

Wegovy HD — The STEP UP Trial

The STEP UP trial enrolled adults with obesity (BMI ≥30) or overweight (BMI ≥27) with at least one weight-related comorbidity. All participants received lifestyle intervention alongside medication.

Key results at 72 weeks:

• Mean body weight loss: 20.7% with semaglutide 7.2mg
• Mean body weight loss: 15.8% with semaglutide 2.4mg (standard Wegovy dose)
• Placebo group: 1.7% weight loss
• 31% improvement over the standard 2.4mg dose

This means Wegovy HD delivers nearly 5 percentage points more weight loss than the dose millions of patients are already taking. For someone weighing 220 pounds, that's the difference between losing roughly 35 pounds and losing 45 pounds.

Zepbound — The SURMOUNT Trials

Zepbound's efficacy data comes from the SURMOUNT program:

SURMOUNT-1 (tirzepatide vs placebo):

• Tirzepatide 15mg: 20.9% mean weight loss at 72 weeks
• Tirzepatide 10mg: 19.5% mean weight loss
• Tirzepatide 5mg: 15.0% mean weight loss
• Placebo: 3.1%

SURMOUNT-5 (tirzepatide vs semaglutide 2.4mg, head-to-head):

• Tirzepatide 15mg: 20.2% mean weight loss
• Semaglutide 2.4mg: 13.7% mean weight loss

The Cross-Trial Comparison Problem

Here's the caveat every honest comparison must acknowledge: there is no head-to-head trial of Wegovy HD vs Zepbound. The numbers — 20.7% for semaglutide 7.2mg and 20.9% for tirzepatide 15mg — come from separate trials with different patient populations, enrollment criteria, and study sites.

Cross-trial comparisons are useful directionally, but they cannot tell you which drug is definitively "better." The SURMOUNT-5 trial that directly compared tirzepatide to semaglutide used the 2.4mg dose, not the 7.2mg dose.

What we can say with confidence:

• Both medications now produce approximately 20% weight loss at their highest approved doses
• The gap that existed before April 2026 (when Wegovy maxed out at 2.4mg) has effectively closed
• Individual response varies significantly — some patients respond dramatically better to one mechanism over the other
• A direct head-to-head trial of semaglutide 7.2mg vs tirzepatide 15mg has not been conducted (and may never be, as neither manufacturer has an incentive to fund one)

Response Rates by Threshold

Weight Loss Threshold	Wegovy HD 7.2mg (STEP UP)	Zepbound 15mg (SURMOUNT-1)
≥5% body weight	~90%	91%
≥10% body weight	~75%	81%
≥15% body weight	~58%	68%
≥20% body weight	~42%	57%

At the higher thresholds (≥20% weight loss), Zepbound's SURMOUNT-1 data shows a somewhat higher responder rate. But again, these are different trials with different populations. The practical difference for most patients may be smaller than these numbers suggest.

What are the side effects of Wegovy HD vs Zepbound?

Both Wegovy HD and Zepbound share the GI side effect profile common to all GLP-1 medications. But there are meaningful differences worth discussing with your prescriber.

GI Side Effects: Head-to-Head Rates

Side Effect	Wegovy HD 7.2mg (STEP UP)	Zepbound 15mg (SURMOUNT-1)
Nausea	~44%	31%
Diarrhea	~30%	23%
Vomiting	~24%	12%
Constipation	~24%	12%
Abdominal pain	~14%	~6%

Tirzepatide (Zepbound) consistently shows lower rates of GI side effects than semaglutide across most studies. This was true at the 2.4mg semaglutide dose, and early data suggests it remains true at 7.2mg — the higher semaglutide dose comes with a proportionally higher GI burden.

For patients who are particularly sensitive to nausea, this is a meaningful differentiator.

For a deeper dive on managing these effects, see our guide to GLP-1 side effects by medication.

The Dysesthesia Question: Wegovy HD's Unique Side Effect

The STEP UP trial flagged a side effect that hasn't been prominent in prior GLP-1 studies: dysesthesia, reported in 18.9% of patients on the 7.2mg dose compared to 4.9% on placebo.

Dysesthesia refers to abnormal sensations — tingling, numbness, prickling, or burning — typically in the hands and feet. It's distinct from neuropathy, though the subjective experience can feel similar.

What patients should know:

• It's dose-related: rates were lower at the 3.6mg dose than at 7.2mg
• It's usually mild to moderate: most patients in STEP UP did not discontinue treatment due to dysesthesia
• The mechanism is unclear: it may relate to rapid metabolic changes, shifts in B-vitamin status, or direct neurological effects of higher-dose semaglutide
• It's new territory: long-term data on whether dysesthesia resolves, persists, or progresses is not yet available

Zepbound does not have an equivalent signal for dysesthesia at any dose level tested in clinical trials.

If you have pre-existing neuropathy, diabetes-related nerve issues, or are concerned about neurological symptoms, discuss this specifically with your prescriber before choosing Wegovy HD.

Serious Adverse Events

Both medications carry similar warnings for:

• Pancreatitis (rare, <1%)
• Gallbladder events (cholelithiasis)
• Thyroid C-cell tumors (boxed warning, based on animal data)
• Suicidal ideation (monitoring recommended)

Neither medication showed a significantly higher rate of serious adverse events than the other in their respective clinical programs.

How do Wegovy HD and Zepbound dosing schedules compare?

How you ramp up to the full dose matters — both for managing side effects and for setting expectations about when you'll see peak results.

Wegovy HD Titration Schedule

Phase	Dose	Duration
Month 1	0.25mg weekly	4 weeks
Month 2	0.5mg weekly	4 weeks
Month 3	1mg weekly	4 weeks
Month 4+	2.4mg weekly	4+ weeks
Step-up	3.6mg weekly	4+ weeks
Target	7.2mg weekly	Ongoing

Total time to reach maximum dose: approximately 6 months from initiation.

For patients already on Wegovy 2.4mg who are stepping up to HD, the path is shorter — you add the 3.6mg intermediate step and then move to 7.2mg, which takes roughly 8-12 additional weeks.

Zepbound Titration Schedule

Phase	Dose	Duration
Month 1	2.5mg weekly	4 weeks
Month 2	5mg weekly	4 weeks
Month 3	7.5mg weekly	4 weeks
Month 4	10mg weekly	4 weeks
Month 5	12.5mg weekly	4 weeks
Target	15mg weekly	Ongoing

Total time to reach maximum dose: approximately 5-6 months from initiation.

Key Differences in Dosing

Zepbound offers more granular dose stepping. With six dose levels vs Wegovy HD's six levels (including the sub-therapeutic titration doses), both provide reasonable flexibility. However, Zepbound's steps are more evenly distributed across its therapeutic range:

• Zepbound: each step is a 2.5mg increment (consistent, predictable)
• Wegovy HD: the jumps are uneven — 0.25 → 0.5 → 1 → 2.4 → 3.6 → 7.2mg. The final jump from 3.6mg to 7.2mg doubles the dose

The large final jump with Wegovy HD (3.6mg to 7.2mg) may catch some patients off guard with increased side effects. Your prescriber may extend the 3.6mg phase if you're experiencing significant GI symptoms before stepping up.

Zepbound lets you "park" at a mid-range therapeutic dose more easily. If 10mg produces adequate weight loss with tolerable side effects, there's no pressure to escalate to 15mg. With Wegovy HD, the intermediate 3.6mg dose was studied primarily as a stepping stone, not as a long-term maintenance dose — though prescribers may use it that way off-label.

How do Wegovy HD and Zepbound compare on price and insurance?

Real costs vary enormously depending on your insurance, employer, and which pharmacy you use. Here's the landscape as of April 2026.

List Prices

	Wegovy HD	Zepbound
Manufacturer list price	~$1,350/mo	$1,060/mo
Without insurance	$1,200–$1,400/mo	$1,060/mo

Manufacturer Programs

Zepbound — LillyDirect: $299/mo for eligible commercially insured patients. This is one of the most aggressive self-pay programs in the GLP-1 space. Patients can order directly through Lilly's platform with a valid prescription.

Wegovy HD — NovoCare Savings: Novo Nordisk's savings program provides variable discounts depending on insurance status. Patients with commercial insurance may pay as little as $0-$25/mo with the savings card. Cash-pay patients face higher costs, and Novo's direct pricing program has not matched LillyDirect's $299/mo price point.

For a complete breakdown of savings strategies, see our guide on how to save money on GLP-1 medications.

Medicare Coverage

Both medications are now covered under Medicare Part D following the Inflation Reduction Act provisions:

• Wegovy HD: Covered — Novo Nordisk Bridge program brings out-of-pocket cost to $50/mo for eligible Medicare beneficiaries
• Zepbound: Covered — Eli Lilly Bridge program brings out-of-pocket cost to $50/mo for eligible Medicare beneficiaries

At Medicare pricing, both medications cost the same. Your choice should be driven by clinical fit rather than cost.

For details on navigating insurance coverage, see our insurance coverage guide for GLP-1 medications.

Commercial Insurance

Coverage rates vary by plan and formulary:

• Wegovy has been on formularies longer and has broader commercial coverage (estimated 65-70% of commercial plans)
• Zepbound coverage has expanded rapidly since launch but still lags slightly (estimated 55-65% of commercial plans)
• Wegovy HD (7.2mg) has been added to most formularies that already cover standard Wegovy, though many plans require step therapy (demonstrating insufficient response on 2.4mg) and prior authorization for the 7.2mg dose

Check your specific plan's formulary before assuming coverage. Many patients have been surprised to learn their plan covers one medication but not the other, or covers a lower dose but requires step therapy before approving the maximum dose.

Telehealth Pricing

Many patients access GLP-1 medications through telehealth platforms. Pricing through these platforms varies, but generally:

• Zepbound through telehealth: $299–$449/mo (with LillyDirect integration)
• Wegovy HD (7.2mg) through telehealth: $1,200–$1,400/mo depending on platform and insurance

Who should choose Wegovy HD over Zepbound?

Wegovy HD may be the better choice if you:

You're already on semaglutide and plateaued. This is the strongest case for Wegovy HD. If you've been on Wegovy 2.4mg (or Ozempic, which uses the same active ingredient) and your weight loss has stalled, stepping up to 3.6mg and then 7.2mg offers a path to additional results without switching drug classes. You already know how your body handles semaglutide.

Your insurance covers Novo Nordisk products but not Lilly products. Formulary coverage is often the deciding factor. If your plan covers Wegovy but not Zepbound, Wegovy HD is the practical choice.

You want to stay in the semaglutide ecosystem. Some patients are on semaglutide for multiple indications — weight management, cardiovascular risk reduction (Wegovy's SELECT trial data), or type 2 diabetes (via Ozempic). Staying on one drug class simplifies your treatment.

You're already tolerating semaglutide well with minimal GI side effects. If your body handles semaglutide comfortably, the step-up to 7.2mg carries less uncertainty than switching to an entirely different mechanism.

The cardiovascular indication matters to you. Wegovy has FDA approval for cardiovascular risk reduction based on the SELECT trial. Zepbound does not (yet). If you have a history of cardiovascular events or significant cardiovascular risk factors, this label indication may be relevant to your prescriber's recommendation.

Who should choose Zepbound over Wegovy HD?

Zepbound may be the better choice if you:

You're starting from scratch. If you haven't tried either medication, Zepbound's dual GLP-1/GIP mechanism offers a theoretical advantage — two pathways for appetite suppression and metabolic improvement rather than one. While the net weight loss numbers are now similar, you may achieve that result with fewer side effects.

You're sensitive to nausea and GI side effects. Across multiple studies, tirzepatide produces lower rates of nausea, vomiting, and diarrhea than semaglutide. If GI tolerance is a concern — especially if you've had trouble tolerating other GI-heavy medications — Zepbound may be easier to live with.

LillyDirect pricing makes financial sense for you. At $299/mo through LillyDirect, Zepbound is significantly more affordable than Wegovy HD for many commercially insured patients. If cost is the primary driver, Zepbound has a clear pricing advantage.

You want more granular dose titration. Zepbound's six evenly spaced dose levels (2.5mg increments) allow your prescriber to fine-tune your dose more precisely. If you tend to be sensitive to medication changes, this flexibility matters.

Dysesthesia concerns you. The 18.9% rate of dysesthesia (tingling/numbness) reported in the STEP UP trial is a new signal. If you have pre-existing peripheral neuropathy, diabetes-related nerve damage, or simply want to avoid neurological side effects, Zepbound doesn't carry this risk.

Your insurance covers Lilly products. Same logic as above, reversed. Formulary access drives real-world medication choice more than any clinical trial.

Can you switch between Wegovy HD and Zepbound?

Yes. Patients switch between semaglutide and tirzepatide regularly, in both directions. There's no biological reason you can't move from one to the other.

Practical considerations when switching:

• Timing: Most prescribers recommend taking your last dose of the current medication, waiting one week (your normal injection day), and starting the new medication at a low dose
• Titration: You'll typically need to titrate up on the new medication even if you were at the maximum dose of your previous one — the dose scales are not interchangeable
• Side effects: Expect some recurrence of GI side effects during the switch, even if you were tolerating your previous medication well
• Insurance: Switching may require a new prior authorization, which can take 1-2 weeks

For detailed switching protocols, see our guide to switching between GLP-1 medications.

What oral GLP-1 options exist alongside Wegovy HD and Zepbound?

Not everyone wants a weekly injection. If you prefer pills, two oral options are now available:

• Oral Wegovy (semaglutide 25mg tablet): FDA-approved in late 2025, delivering about 16.6% weight loss in the OASIS 4 trial. Less than Wegovy HD or Zepbound, but no needles.
• Orforglipron (Eli Lilly): An oral non-peptide GLP-1 agonist priced at approximately $149/mo — dramatically less expensive than injectable options. Early trial data shows ~15% weight loss.

Neither oral option matches the ~20% weight loss of Wegovy HD or Zepbound at maximum doses. But for patients who are needle-averse or cost-constrained, they represent meaningful alternatives.

For a detailed comparison, see our Wegovy pill vs orforglipron guide.

The Bottom Line

Wegovy HD and Zepbound are now the two most effective FDA-approved weight loss medications, both delivering approximately 20% body weight loss. There is no wrong choice between them. The right choice depends on your specific situation:

If cost is the primary driver → Zepbound via LillyDirect ($299/mo) offers the best cash-pay value for a ~20% weight loss medication. Until Novo Nordisk matches this pricing for Wegovy HD, the financial advantage belongs to Zepbound.

If you're already on semaglutide → Wegovy HD is the natural step-up. You know your body tolerates the drug, you avoid switching classes, and you gain an additional ~5 percentage points of weight loss without starting over.

If you're starting fresh and both are accessible → Consider both, with a slight edge to Zepbound on tolerability (lower GI side effect rates, no dysesthesia signal). Discuss with your prescriber whether the dual mechanism or the familiar semaglutide pathway makes more sense for your health profile.

If you're on Medicare → Both cost $50/mo through Bridge programs. Choose based on clinical fit, not cost.

If you have cardiovascular risk factors → Wegovy (including HD) has the SELECT trial cardiovascular data behind it. Zepbound does not yet have an equivalent cardiovascular outcome trial.

The best medication is the one you can access, afford, tolerate, and stay on long-term. Talk to your prescriber about which profile fits your medical history, budget, and goals.

For the original comparison of standard-dose Wegovy vs Zepbound, see our Zepbound vs Wegovy guide. For a comprehensive overview of Wegovy HD, visit our Wegovy HD semaglutide 7.2mg guide.

Frequently Asked Questions

Is Wegovy HD the same as regular Wegovy?

Wegovy HD uses the same active ingredient — semaglutide — but at a higher maximum dose. Standard Wegovy tops out at 2.4mg per week. Wegovy HD adds two new dose levels: 3.6mg and 7.2mg. The 7.2mg dose delivers approximately 20.7% weight loss compared to 15.8% with 2.4mg, based on the STEP UP trial. Think of it as Wegovy with the ceiling raised.

Has there been a direct head-to-head trial of Wegovy HD vs Zepbound?

No. The SURMOUNT-5 trial compared tirzepatide (Zepbound) to semaglutide 2.4mg (standard Wegovy), not the 7.2mg HD dose. The 20.7% and 20.9% weight loss figures come from separate trials (STEP UP and SURMOUNT-1 respectively). A direct comparison trial of the two highest doses has not been announced.

What is dysesthesia and should I be worried about it?

Dysesthesia is an abnormal sensation — tingling, numbness, prickling, or burning — most commonly in the hands and feet. It was reported in 18.9% of patients taking Wegovy HD (7.2mg) in the STEP UP trial, compared to 4.9% on placebo. In most cases it was mild to moderate and did not lead to treatment discontinuation. However, if you have pre-existing neuropathy or nerve-related conditions, discuss this risk specifically with your doctor before starting Wegovy HD.

Which is cheaper: Wegovy HD or Zepbound?

For most patients paying out of pocket, Zepbound is currently cheaper. LillyDirect offers Zepbound at $299/mo for eligible patients. Wegovy HD pricing is still stabilizing, with list prices expected around $1,350/mo. Novo Nordisk's savings programs reduce costs for commercially insured patients, but have not matched LillyDirect's price point. On Medicare, both cost $50/mo through their respective Bridge programs.

Can I switch from Wegovy to Zepbound (or vice versa)?

Yes. Patients switch between semaglutide and tirzepatide in both directions. Your prescriber will typically have you take your last dose of the current medication, wait one week, then start the new medication at a low dose and titrate up. Expect some return of GI side effects during the transition. You may also need a new prior authorization from your insurance. See our switching guide for detailed protocols.

Should I step up to Wegovy HD or switch to Zepbound if I've plateaued on Wegovy 2.4mg?

Both are reasonable options. Stepping up to Wegovy HD (7.2mg) is the simpler path — you're staying on the same drug at a higher dose, which typically means a smoother transition and fewer unexpected side effects. The STEP UP trial showed 20.7% weight loss at 7.2mg vs 15.8% at 2.4mg, so there's clear additional benefit. Switching to Zepbound means changing drug classes entirely, which introduces more variability but also offers the dual-mechanism advantage and lower GI side effect rates. Discuss both options with your prescriber.

Does Wegovy HD have the same cardiovascular benefits as regular Wegovy?

Wegovy's cardiovascular risk reduction indication is based on the SELECT trial, which used the 2.4mg dose. The FDA has extended the Wegovy label to include HD, and the cardiovascular indication applies to the brand overall. However, no separate cardiovascular outcomes trial has been conducted specifically at the 7.2mg dose. Whether the higher dose provides additional cardiovascular benefit beyond 2.4mg is not yet established.

Are there any long-term safety concerns unique to Wegovy HD?

Wegovy HD was approved via the FDA's National Priority Voucher program, which accelerated the review timeline to 54 days. The STEP UP trial provided 72-week safety data, which is standard for weight loss medications. Long-term safety data beyond 72 weeks at the 7.2mg dose is not yet available. The dysesthesia signal (18.9%) is new and warrants monitoring. Patients and prescribers should report any unexpected neurological symptoms through normal pharmacovigilance channels.